Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

PURPOSE: To assess safety/tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of DEBIO1143, an antagonist of inhibitor apoptosis proteins. METHODS: This first-in-man study in patients with advanced cancer used an accelerated dose titration design. DEBIO1143 was given o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: Hurwitz, Herbert I., Smith, David C., Pitot, Henry C., Brill, Jeffrey M., Chugh, Rashmi, Rouits, Elisabeth, Rubin, Joseph, Strickler, John, Vuagniaux, Gregoire, Sorensen, J. Mel, Zanna, Claudio
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365270/
https://ncbi.nlm.nih.gov/pubmed/25716544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2709-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars